Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women's health and wellness, primarily focusing on breast aesthetics and reconstruction. The company's mission is to advance women's health through science, engineering, and technology. Headquartered in Austin, Texas, Establishment Labs operates with a global reach, delivering its products to plastic surgeons in over 100 countries.

The company's core offerings include a portfolio of advanced silicone gel-filled breast implants, marketed under the brand name Motiva Implants®. Beyond implants, Establishment Labs also provides the Motiva Flora® tissue expander, Mia Femtech™ for minimally invasive breast enhancement, Divina 3D surgical simulation systems, and distributes the Puregraft line of products for autologous adipose tissue harvesting and redistribution. These products cater to the breast aesthetics and reconstruction market segments.

In recent leadership news, Peter Caldini was appointed Chief Executive Officer effective May 7, 2025. The company achieved a significant milestone in April 2026, surpassing five million Motiva devices in the market. Further demonstrating its market presence, Establishment Labs was added to the U.S. small-cap Russell 2000® Index in June 2026. The company also appointed Taylor Harris to its Board of Directors in June 2026 and refinanced its credit facility in April 2026. Motiva implants received FDA approval for breast augmentation in September 2024, with an application for breast reconstruction submitted in December 2025. Establishment Labs continues to report strong revenue growth and aims for free cash flow positivity in the second half of 2026.